Skip to main content

Table 3 Cases of ROS received pregnancy through different treatments

From: Case report: Birth achieved after effective ovarian stimulation combined with dexamethasone in a patient with resistant ovary syndrome

Author

Patient No.

Age at intake

Type of infertility

BMI

(kg/m2)

Basal

AFC

AMH

(μg/L)

Ovarian histology

E2

FSH

Ig-FSHR

Infertility treatments before pregnant

Medication/hormonal pretreatment

Result

Amos, W. L., Jr. (1985) [12]

1

41

Secondary

NA

NA

NA

NA

NA

88.4 IU/L

NA

HRT

Estrogens, medroxyprogesterone acetate

Liveborn

Jequier, A. M. (1990) [6]

2

28

Secondarya

NA

NA

NA

NA

31–52 pmol/L

125 U/L

NA

HRT

4 cycles (Mestranol + Norethisterone)

Liveborn

3

30

Secondarya

NA

NA

NA

normal ovarian stroma and follicles

76 pmol/L

range seen in postmenopausal women

NA

HRT

Mestranol + Norethisterone

Normal pregnancy

Nawroth, F. and R. Sudik (1999) [8]

4

32

Secondary

NA

NA

NA

NA

NA

NA

NA

HRT

2 mg estradiol valerate and 2 mg estradiol valerate/0.15 mg levonorgestrel

Liveborn

Mueller, A., et al. (2003) [9]

5

26

Primary

NA

NA

NA

normal density of

follicles

NA

70 IU/L

NA

HRT

2 mg estradiol valerate and 0.5 mg norgestrel per day administered sequentially

Liveborn

Aslam, M. F., et al. (2004) [10]

6

19

Secondary

NA

NA

NA

NA

NA

133.9 U/L

NA

HRT

2 mg estradiol valerate and 0.5 mg norgestrel

Twice liveborn

7

24

Secondary

27

NA

NA

NA

NA

Higher than normal

NA

HRT

estradiol valerate and norgestrel

Normal pregnancy

Zielinska, D. and I. Rzepka-Gorska (2011) [11]

8

31

Secondary

NA

NA

NA

NA

18.1 pg/ml

58.2 IU/mL

NA

HRT

(spontaneous recovery of ovarian function after HRT)

liveborn

Ezeh, U. I. O. and A. J. Breeson (1995) [7]

9

32

22

NA

NA

NA

NA

39 pmol/L

95–115 IU/L

NA

Ovarian Hyperstimulation

eight ampoules of

menotrophin (Pergonal) daily for 14 days

Liveborn

Rogenhofer, N., et al. (2015) [4]

10

26

Secondary

22

15

2.1

NA

28.7 pg/mL

50.8 U/mL

antibodies directed to hMG but not to recFSH

Controlled Ovarian Hyperstimulation and IVF

GnRH analogue

Narfarelin, recombinant follitropin beta, hMG

liveborn

Grynberg, M., et al. (2013) [13]

11

29

primary

normal

23 and 18

4.50 and 4.36

NA

< 15

40.3 and 38.4 mIU/mL

NA

IVM

17ß-E2, hCG

liveborn

Li, Y., et al. (2016) [14]

12

33

Secondarya

NA

25

12.27

NA

260.57 pmol/l

41.99 IU/L

NA

IVM

estradiol valerate, hCG

liveborn

Galvao, A., et al. (2018) [15]

13

29

primary

27.7

37

8.6

NA

NA

27.7 IU/L

NA

IVM

none

liveborn

14

36

primary

18.9

40

2.11

NA

NA

7.9 IU/L

NA

IVM

HP-hMG 150 IU/day for 5 days, hCG

liveborn

15

23

primary

24.8

50

2.88

NA

NA

49.1 IU/L

NA

IVM

17ß-E2, hCG

Twice liveborn

C. Flageole., et al. (2019) [23]

16

31

primary

NA

19

3.24 ng/mL

NA

NA

43–62 IU/L

NA

IVM

hMG (Menopur®) plus rFSH (Gonal F®), hCG

liveborn

  1. Abbreviations: BMI body mass index, AFC antral follicle count, AMH anti-müllerian hormone, HRT hormone replacement therapy, IVM in vitro maturation, ART assisted reproductive technologies, rFSH recombinant follicle stimulating hormone, FSHR follicle-stimulating hormone receptor, GnRH gonadotropin-releasing hormone, hCG human chorionic gonadotropin, hMG human menopausal gonadotropin, HP-hMG highly purified human menopausal gonadotropin, 17ß-E2 estradiol-17ß, NA not applicable
  2. aOne live birth after spontaneous birth